Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Interchangeability Requirements Pushed At Inflectra Review

Executive Summary

Celltrion is not seeking interchangeable status, but it had data on a single transition from EU-approved Remicade; however, FDA's advisors said data on multiple switches between products would more accurately reflect real-world clinical practice.

Advertisement

Related Content

Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Extrapolated Biosimilar Indications Won't Get More US Post-Marketing Requirements
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel